Among the company’s developing portfolio of products is SILKBridge, a first-to-market, silk-based graft for peripheral nerve repair, which is anticipated to be available for clinical use in 2023. This tissue engineered technology is based on pure silk fibroin that merges a deep-rooted cultural tradition and know-how with the most advanced technologies creating a highly purified material needed for biomedical applications, without the need for chemical cross-linking reactions that alter the protein.

KLISBio is focused on developing innovative solutions that solve prominent, unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed.

“We’ve developed a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications,” said Gabriele Grecchi, CEO and co-founder. “KLISBio is significantly contributing to healthcare innovation, disrupting the restorative surgical market by bringing innovation via a truly versatile biocompatible material, robust scientific and operational excellence.”

KLISBio is powered by an international group of world leaders in medtech including Grecchi, CEO; Antonio Alessandrino, Chief Technology Officer; Guiliano Freddi, Chief Scientific Officer; Jason Schense, Chief Business Officer. The company recently announced that Rodrigo Bianchi will serve as Chairman of the Board, coming to KLISBio with more than three decades’ experience in global healthcare.

In addition to the strong leadership team, KLISBio works with physicians, engineers, researchers, chemists and biologists worldwide who represent excellence in the biomedical space. The company holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers.